Found: 31
Select item for more details and to access through your institution.
Phase II trial of single-agent foretinib (GSK1363089) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
- Published in:
- Investigational New Drugs, 2013, v. 31, n. 2, p. 417, doi. 10.1007/s10637-012-9861-3
- By:
- Publication type:
- Article
Inhibition of topoisomerase II α activity and induction of apoptosis in mammalian cells by semi-synthetic andrographolide analogues.
- Published in:
- 2013
- By:
- Publication type:
- Journal Article
Mechanisms of acquired resistance to insulin-like growth factor 1 receptor inhibitor in MCF-7 breast cancer cell line.
- Published in:
- Investigational New Drugs, 2013, v. 31, n. 2, p. 293, doi. 10.1007/s10637-012-9855-1
- By:
- Publication type:
- Article
The vascular disrupting agent ombrabulin (AVE8062) enhances the efficacy of standard therapies in head and neck squamous cell carcinoma xenograft models.
- Published in:
- Investigational New Drugs, 2013, v. 31, n. 2, p. 273, doi. 10.1007/s10637-012-9852-4
- By:
- Publication type:
- Article
Enhanced killing of cervical cancer cells by combinations of methyl jasmonate with cisplatin, X or alpha radiation.
- Published in:
- Investigational New Drugs, 2013, v. 31, n. 2, p. 333, doi. 10.1007/s10637-012-9870-2
- By:
- Publication type:
- Article
Differences in drug approval processes of 3 regulatory agencies: a case study of gemtuzumab ozogamicin.
- Published in:
- Investigational New Drugs, 2013, v. 31, n. 2, p. 473, doi. 10.1007/s10637-012-9877-8
- By:
- Publication type:
- Article
The prostate cancer blocking potential of the histone deacetylase inhibitor LBH589 is not enhanced by the multi receptor tyrosine kinase inhibitor TKI258.
- Published in:
- Investigational New Drugs, 2013, v. 31, n. 2, p. 265, doi. 10.1007/s10637-012-9851-5
- By:
- Publication type:
- Article
A Phase I trial of the kinesin spindle protein (Eg5) inhibitor AZD4877 in patients with solid and lymphoid malignancies.
- Published in:
- Investigational New Drugs, 2013, v. 31, n. 2, p. 355, doi. 10.1007/s10637-012-9821-y
- By:
- Publication type:
- Article
Unexpected renal toxicity associated with SGX523, a small molecule inhibitor of MET.
- Published in:
- Investigational New Drugs, 2013, v. 31, n. 2, p. 363, doi. 10.1007/s10637-012-9823-9
- By:
- Publication type:
- Article
Pre-operative chemoradiation followed by post-operative adjuvant therapy with tetrathiomolybdate, a novel copper chelator, for patients with resectable esophageal cancer.
- Published in:
- Investigational New Drugs, 2013, v. 31, n. 2, p. 435, doi. 10.1007/s10637-012-9864-0
- By:
- Publication type:
- Article
The non-genotoxic activator of the p53 pathway Nutlin-3 shifts the balance between E2F7 and E2F1 transcription factors in leukemic cells.
- Published in:
- 2013
- By:
- Publication type:
- Report
The inhibitor of Ca-dependent K channels TRAM-34 blocks growth of hepatocellular carcinoma cells via downregulation of estrogen receptor alpha mRNA and nuclear factor-kappaB.
- Published in:
- 2013
- By:
- Publication type:
- Report
A phase I, dose-finding study of sunitinib combined with cisplatin and 5-fluorouracil in patients with advanced gastric cancer.
- Published in:
- Investigational New Drugs, 2013, v. 31, n. 2, p. 390, doi. 10.1007/s10637-012-9830-x
- By:
- Publication type:
- Article
The PARP inhibitor ABT-888 synergizes irinotecan treatment of colon cancer cell lines.
- Published in:
- 2013
- By:
- Publication type:
- Report
A Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2013, v. 31, n. 2, p. 409, doi. 10.1007/s10637-012-9904-9
- By:
- Publication type:
- Article
Inhibition of cancer growth and induction of apoptosis by BGP-13 and BGP-15, new calcipotriene-derived vitamin D analogs, in-vitro and in-vivo studies.
- Published in:
- Investigational New Drugs, 2013, v. 31, n. 2, p. 247, doi. 10.1007/s10637-012-9839-1
- By:
- Publication type:
- Article
Eribulin mesylate pharmacokinetics in patients with solid tumors receiving repeated oral ketoconazole.
- Published in:
- Investigational New Drugs, 2013, v. 31, n. 2, p. 381, doi. 10.1007/s10637-012-9829-3
- By:
- Publication type:
- Article
Gemcitabine alone and/or containing chemotherapy is efficient in refractory or relapsed NK/T-cell lymphoma.
- Published in:
- Investigational New Drugs, 2013, v. 31, n. 2, p. 469, doi. 10.1007/s10637-012-9889-4
- By:
- Publication type:
- Article
Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma.
- Published in:
- Investigational New Drugs, 2013, v. 31, n. 2, p. 425, doi. 10.1007/s10637-012-9862-2
- By:
- Publication type:
- Article
A Phase I, open-label, dose escalation study of afatinib, in a 3-week-on/1-week-off schedule in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2013, v. 31, n. 2, p. 399, doi. 10.1007/s10637-012-9890-y
- By:
- Publication type:
- Article
Erratum to: Inhibition of cancer growth and induction of apoptosis by BGP-13 and BGP-15, new calcipotriene-derived vitamin D analogs, in-vitro and in-vivo studies.
- Published in:
- 2013
- By:
- Publication type:
- Correction Notice
Phase I pharmacokinetic and pharmacodynamic study of cetuximab, irinotecan and sorafenib in advanced colorectal cancer.
- Published in:
- Investigational New Drugs, 2013, v. 31, n. 2, p. 345, doi. 10.1007/s10637-012-9820-z
- By:
- Publication type:
- Article
Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2013, v. 31, n. 2, p. 370, doi. 10.1007/s10637-012-9825-7
- By:
- Publication type:
- Article
Vascular disrupting activity and the mechanism of action of EHT 6706, a novel anticancer tubulin polymerization inhibitor.
- Published in:
- Investigational New Drugs, 2013, v. 31, n. 2, p. 304, doi. 10.1007/s10637-012-9858-y
- By:
- Publication type:
- Article
Population pharmacokinetic modeling of Sepantronium bromide (YM155), a small molecule survivin suppressant, in patients with non-small cell lung cancer, hormone refractory prostate cancer, or unresectable stage III or IV melanoma.
- Published in:
- Investigational New Drugs, 2013, v. 31, n. 2, p. 443, doi. 10.1007/s10637-012-9867-x
- By:
- Publication type:
- Article
Acknowledgement of Reviewers 2011.
- Published in:
- Investigational New Drugs, 2013, v. 31, n. 2, p. 491, doi. 10.1007/s10637-012-9905-8
- Publication type:
- Article
Efficacy of substituted 9-aminoacridine derivatives in small cell lung cancer.
- Published in:
- Investigational New Drugs, 2013, v. 31, n. 2, p. 285, doi. 10.1007/s10637-012-9854-2
- By:
- Publication type:
- Article
Inhibition of topoisomerase II α activity and induction of apoptosis in mammalian cells by semi-synthetic andrographolide analogues.
- Published in:
- Investigational New Drugs, 2013, v. 31, n. 2, p. 320, doi. 10.1007/s10637-012-9868-9
- By:
- Publication type:
- Article
Tumor regression with a combination of drugs interfering with the tumor metabolism: efficacy of hydroxycitrate, lipoic acid and capsaicin.
- Published in:
- Investigational New Drugs, 2013, v. 31, n. 2, p. 256, doi. 10.1007/s10637-012-9849-z
- By:
- Publication type:
- Article
Erratum to: Silymarin attenuated mast cell recruitment thereby decreased the expressions of matrix metalloproteinases-2 and 9 in rat liver carcinogenesis.
- Published in:
- 2013
- By:
- Publication type:
- Correction Notice
Clinical trial design in biosimilar drug development.
- Published in:
- Investigational New Drugs, 2013, v. 31, n. 2, p. 479, doi. 10.1007/s10637-012-9899-2
- By:
- Publication type:
- Article